Combining serum miR-144-3p and miR-652-3p as potential biomarkers for the early diagnosis and stratification of acute cellular rejection in heart transplantation patients

Abstract Background There is a dire need for specific, noninvasive biomarkers that can accurately and early detect cardiac acute cellular rejection (ACR). Previously, we described miR-144-3p as an excellent candidate to Grade ≥2R ACR. Purpose Now, investigated the combination of with other differentially expressed serum miRNA previously improve diagnostic accuracy, mainly in mild avoid reaching severe stages. Methods We selected miR-652-3p, miR-6747-3p miR-221-3p from preliminary RNA-seq study be validated by RT-qPCR on 212 consecutive samples transplantation recipients undergoing routine endomyocardial biopsies subsequently combine them results investigate their capability. Results confirmed miR-652-3p overexpression (p<0.0001) its capability discriminate between patients without ACR any grade (p<0.0001), but not or miR-221-3p. The combined levels were significantly higher regardless posttransplantation time (p<0.0001). This resulted efficacy 1R (AUC=0.794) (AUC=0.892) was superior each biomarker alone. Furthermore, it strong independent predictor (odds ratio 10.950, p<0.0001) 14.289, p<0.01). Conclusions demonstrated appropriate blood-based exhibit greater efficiency diagnosis. detection abnormal expression sensitivity at stage contribute increasing lower grades. Funding Acknowledgement Type funding sources: Public grant(s) – National budget only. Main source(s): Institute Health Carlos III European Regional Development Fund (ERDF)